Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

1.010 +0.010 (+1.00%)
Streaming Delayed Price Updated: 9:54 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TScan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With ↗
Although lesser-known ideas present high risks, these cheap stocks under $10 could be intriguing for the calculating speculator. 
Via InvestorPlace
News headline image
TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗
TCRX stock results show that TScan Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
TScan Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Recap: TScan Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
Company to host virtual KOL event featuring Monzr M. Al Malki, M.D., on Monday, December 11, at 8:00 a.m. ET to discuss the data presented at the ASH Annual Meeting 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy 
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
TScan Therapeutics Announces Transition of Chief Financial Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>